{"entity":{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","aka":[],"tldr":"Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.","summary":"Rahul Aggarwal is Associate Director for Clinical Sciences at the UCSF Helen Diller Family Comprehensive Cancer Center. A medical oncologist specialising in prostate cancer, neuroendocrine prostate cancer and PSMA theranostics, he leads UCSF's early-phase and prostate cancer clinical research and defined treatment-emergent small-cell neuroendocrine prostate cancer, the way tumours transform to escape hormone therapy. His papers include a multi-institutional prospective study characterising that disease clinically and genomically, and a report on heterogeneous flare in PSMA PET tracer uptake after starting androgen pathway blockade. He leads PSMA radioligand and combination trials, including with lutetium-177 vipivotide tetraxetan.","asOf":"2026-09-08","links":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma","androgen-receptor"],"drugs":["pluvicto"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["european-urology-oncology"],"dependsOn":[],"notes":[],"role":"Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center","institutionId":"ucsf","specialisms":["Prostate cancer","Neuroendocrine prostate cancer","PSMA theranostics"],"profiles":[{"label":"UCSF profile","url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal"}],"papers":[{"title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","journal":"Journal of Clinical Oncology","year":2018,"url":"https://doi.org/10.1200/JCO.2017.77.6880","doi":"10.1200/JCO.2017.77.6880"},{"title":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","journal":"European Urology Oncology","year":2018,"url":"https://doi.org/10.1016/j.euo.2018.03.010","doi":"10.1016/j.euo.2018.03.010"}]},"route":"/people/rahul-aggarwal/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}],"journal":[{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/"}]}}